NL8901975A - Werkwijze voor de bereiding van tegen kinkhoest-beschermende antigenen. - Google Patents
Werkwijze voor de bereiding van tegen kinkhoest-beschermende antigenen. Download PDFInfo
- Publication number
- NL8901975A NL8901975A NL8901975A NL8901975A NL8901975A NL 8901975 A NL8901975 A NL 8901975A NL 8901975 A NL8901975 A NL 8901975A NL 8901975 A NL8901975 A NL 8901975A NL 8901975 A NL8901975 A NL 8901975A
- Authority
- NL
- Netherlands
- Prior art keywords
- preparation
- antigens
- pertussis
- microbe
- suspension
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims description 28
- 102000036639 antigens Human genes 0.000 title claims description 28
- 108091007433 antigens Proteins 0.000 title claims description 28
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title description 24
- 230000001681 protective effect Effects 0.000 title description 18
- 230000008569 process Effects 0.000 title description 3
- 201000005702 Pertussis Diseases 0.000 claims description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 24
- 239000000644 isotonic solution Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 claims description 9
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 claims description 9
- 230000002779 inactivation Effects 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229940032024 DPT vaccine Drugs 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 231100000563 toxic property Toxicity 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229940124847 Diphtheria-Tetanus vaccine Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8910234A FR2650184A1 (fr) | 1989-07-31 | 1989-07-28 | Procede pour la preparation d'antigenes protecteurs de la coqueluche |
| NL8901975A NL8901975A (nl) | 1989-07-31 | 1989-07-31 | Werkwijze voor de bereiding van tegen kinkhoest-beschermende antigenen. |
| HU393989A HU53931A (OSRAM) | 1989-07-31 | 1989-08-02 | |
| DE19893926206 DE3926206A1 (de) | 1989-07-31 | 1989-08-08 | Verfahren zur herstellung von keuchhusten-schutzantigenen |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8901975 | 1989-07-31 | ||
| NL8901975A NL8901975A (nl) | 1989-07-31 | 1989-07-31 | Werkwijze voor de bereiding van tegen kinkhoest-beschermende antigenen. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8901975A true NL8901975A (nl) | 1991-02-18 |
Family
ID=19855129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8901975A NL8901975A (nl) | 1989-07-31 | 1989-07-31 | Werkwijze voor de bereiding van tegen kinkhoest-beschermende antigenen. |
Country Status (4)
| Country | Link |
|---|---|
| DE (1) | DE3926206A1 (OSRAM) |
| FR (1) | FR2650184A1 (OSRAM) |
| HU (1) | HU53931A (OSRAM) |
| NL (1) | NL8901975A (OSRAM) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4429046A (en) * | 1982-07-26 | 1984-01-31 | American Cyanamid Company | Large scale cultivation of Bordetella pertussis cells for vaccine production |
-
1989
- 1989-07-28 FR FR8910234A patent/FR2650184A1/fr active Pending
- 1989-07-31 NL NL8901975A patent/NL8901975A/nl not_active Application Discontinuation
- 1989-08-02 HU HU393989A patent/HU53931A/hu unknown
- 1989-08-08 DE DE19893926206 patent/DE3926206A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HU53931A (OSRAM) | 1990-12-28 |
| DE3926206A1 (de) | 1991-02-14 |
| FR2650184A1 (fr) | 1991-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rowley | Phagocytosis | |
| Miller et al. | Experimental meningococcal infection in the mouse | |
| Rowley | The role of opsonins in non-specific immunity | |
| Muschel et al. | Human blood group substance B and Escherichia coli 086 | |
| Harris-Smith et al. | Production in vitro of the toxin of Bacillus anthracis previously recognized in vivo | |
| KR890004019B1 (ko) | 요로 감염 치료용 백신의 제조방법 | |
| Young et al. | Interaction of salmonellae and schistosomes in hostparasite relations | |
| Smith et al. | Comparative effect of two strains of C. parvum on phagocytic activity and tumour growth | |
| Eiseman | Intravenous infusion of coconut water | |
| Youmans et al. | The inactivation of isoniazid by filtrates and extracts of mycobacteria | |
| Mandel et al. | INHIBITION OF THEILER'S ENCEPHALOMYELITIS VIRUS (GDVII STRAIN) OF MICE BY AN INTESTINAL MUCOPOLYSACCHARIDE: I. Biological Properties and Mechanism of Action | |
| CN101618213B (zh) | 麻疹腮腺炎乙型脑炎联合减毒活疫苗及其制备方法 | |
| Schweiger et al. | Role of non-protein nitrogen in the synthesis of haemoglobin in the reticulocyte in vitro | |
| NL8901975A (nl) | Werkwijze voor de bereiding van tegen kinkhoest-beschermende antigenen. | |
| RU2000799C1 (ru) | Стимул тор иммунологической резистентности организма | |
| Rurangirwa et al. | Treatment of contagious caprine pleuropneumonia | |
| Ross | Photodynamic action of methylene blue on antipneumococcal serum | |
| JPS6234725B2 (OSRAM) | ||
| VI | The Inhibition of the Bactericidal Power of Human and Animal Sera by Antigenic Substances Obtained from Organisms of the Typhoid-Salmonella Group | |
| Laurell | Jules Bordet--a giant in immunology. | |
| Corper et al. | Autolytic tuberculin, its properties and the significance of its mode of formation | |
| RU2045278C1 (ru) | Средство, потенцирующее противотурберкулезное действие изониазида | |
| EP0747477A4 (en) | TRICHODERMA HARZIEANUM RIFAI STEM, METHOD FOR RECEIVING L-LYSINE-ALPHA-OXIDASE AS A VIRAL AND BACTERIAL ACTIVITY INHIBITOR, IMMUNOMODULATOR AND SKIN HEALING AGENT | |
| Dakin | Biochemistry and war problems | |
| Smith | Studies on the chemotherapy of silver and arsenic compounds in experimental tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |